138 results about "Enteritides" patented technology

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The invention provides a decapterus maruadsi deepwater net cage culture method, and belongs to the technical field of decapterus maruadsi culture. According to the method, the submersible net cage is adopted, the decapterus maruadsi is located in the optimal growth water layer at the temperature of 20-25 DEG C all the year round according to rising and falling of seasons (surface water temperature), a guide pipe is adopted for fixed-point feed feeding, and the feed coefficient is reduced to 1.25 or below. According to the method, a water temperature-feeding amount-allicin-probiotics coupling model is established, the enteritis incidence rate in the high-temperature period is controlled within 2%, and annual continuous growth of decapterus maruadsi in deep and far sea is achieved.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

The microorganism strain Pediococcus acidilactici TAK 589 CoccobEst is a new antimicrobial and antioxidant probiotic, CoccobEst inhibits the growth of the enteropathogens L. monocytogenes, E. coli, S. enteritidis, S. typhimurium, S. sonnei, S. aureus, E. faecalis and C. sakazakii, but does not inhibit lactobacilli of natural intestinal microbiota. The strain's antimicrobial properties are enhanced by periplasmic peptidoglycan hydrolases with proteolytic activity. CoccobEst is used as a zootechnieai feed additive to prevent bacterial infections in the gastrointestinal tract of farm animals and pets and to prevent and reduce diarrhea. CoccobEst has highly active antioxidant defense system, increasing the redox activity of glutathione and reducing oxidative stress in cells. Therefore, CoccobEst is used as a food supplement or functional food for humans to prevent bacterial infections of the gastrointestinal tract and to prevent and reduce oxidative stress. In addition, CoccobEst is used as a starter culture in fermentation of vegetables.

The present disclosure provides a method of reducing, preventing or treating an intestinal infection, preventing or treating a disease associated with protozoan parasite of the genus Eimeria, inhibiting an oocyst sporulation of a protozoan parasite or preventing a sporozoite invasion or reproduction, preventing or treating coccidiosis, promoting growth performance, controlling, treating and / or preventing necrotic enteritis in a subject, comprising administering to the subject an effective amount of a composition comprising a Crassocephalum rabens (CR), a bioactive extract thereof (CRE), an active ingredient(s) contained in a CR (CR_API) or CRE (CRE_API), a combination of two or more of a CR, a CRE, a CR_API and a CRE_API, or one or more of a-linolenic acid, citric acid, lactic acid, mannitol, palmitic acid, aspartic acid and 1-monomyristin.

The application discloses application of T1FR protein in inhibition of Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae, and relates to the field of biotechnology. T1fr The biological factor T1FR protein encoded by the gene can inhibit Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae adhesion factors, and can effectively reduce the use of antibiotics and relieve the drug resistance of Klebsiella pneumoniae and Salmonella by inhibiting pathogenic bacteria adsorption and colonization in human and animal tissues, thereby providing a theoretical basis and an important reference scheme for controlling bacterial infection and biofilm formation.

The present invention relates to immunogenic compositions comprising antigens derived from Salmonella enterica serotype tiphimurium (S. Typhimurium), Salmonella enterica serotype enteritidis (S. Enteritidis), and Salmonella enterica serotype typhi (S. Typhi). The present invention further relates to methods and compositions comprising GMMA for boosting the immune response to the S. Typhi antigen, vaccines and methods comprising immunogenic compositions, and the use of immunogenic compositions.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The invention provides an application of N4BP1 in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and particularly provides an application of N4BP1 as an inhibition target in preparation of an anti-enteritis drug. Researches show that the deletion of N4BP1 can alleviate colon pathological changes and weight loss caused by DSS, increase the survival days of mice, and reduce the generation of inflammatory factors and chemotactic factors. In addition, DSS can cause increase of N4BP1 expression in mice. Therefore, occurrence and development of enteritis can be inhibited by knocking out the N4BP1, the N4BP1 inhibitor or the N4BP1 neutralizing antibody, namely, the N4BP1 can become a new target spot for treating enteritis. Meanwhile, the expression of the N4BP1 can also be used as a new index for enteritis detection.

The invention belongs to the technical field of disease control in aquaculture, and particularly relates to a hippocampus enteritis pathogen separation and identification and medication screening method based on a high-throughput sequencing technology, which comprises the following steps: collecting intestinal tissues of a diseased hippocampus and a healthy hippocampus, respectively preparing tissue homogenate, and freezing for preservation; the method comprises the following steps: extracting DNA (Deoxyribose Nucleic Acid) of microorganisms of an intestinal tissue sample, performing 16SrDNA high-throughput sequencing, analyzing intestinal flora composition, and determining dominant bacteria; selecting and screening a culture medium according to dominant bacteria, and performing pathogenic bacterium separation and purification on intestinal tissues of the diseased hippocampus; dNA of the purified strain is extracted, 16S rDNA amplification and sequencing are carried out, and the species of pathogenic bacteria are identified through sequence comparison; according to the method, the diversity and abundance differences of microorganisms in the sick hippocampus and the healthy hippocampus are compared through a high-throughput sequencing technology, and targeted separation, identification and drug sensitivity screening are further carried out by taking statistically significant difference bacteria as the guidance of potential pathogenic bacteria.

The application discloses a gene prdR for regulating myxobacteria predation and a protein coded by the gene, and belongs to the technical field of biotechnology. The mutant DK10 with significantly improved predation capacity is obtained by using the strategy of adaptive evolution; genetic variation sites of the mutant DK10 are analyzed by using the bacterial genome resequencing technology, and functions of the genetic variation sites are researched by using the gene knockout technology, and it is found that the gene deletion of MXAN_2902 (prdR, the nucleotide sequence is shown as SEQ ID NO. 1) significantly enhances the predation capacity of Myxococcus xanthus. The nucleic acid sequence and the amino acid sequence of the transcriptional activator PrdR for regulating the predation of Myxococcus xanthus are disclosed, and the functional strain of Myxococcus xanthus capable of efficiently predating Salmonella enteritidis can be developed by using the prdR gene, and a new strategy is provided for the prevention and control of drug-resistant HVPG pathogenic bacteria.

The application discloses application of a natural oyster zinc peptide product in preparation of a medicine for preventing and treating enteritis. The application verifies the function of the natural oyster zinc peptide product in preventing and treating enteritis through animal experiments, the natural oyster zinc peptide product can improve the apparent symptoms of ulcerative colitis of mice caused by DSS by regulating the oxidation stress level, relieving the inflammatory reaction, maintaining the intestinal barrier and reducing the cell apoptosis, and the natural oyster zinc peptide product can also regulate the intestinal flora and metabolic products of the intestinal flora of the enteritis mice, so that the intestinal inflammation is relieved. The natural oyster zinc peptide product used in the application has good safety, compared with common anti-inflammatory and immunity-enhancing medicines, the natural oyster zinc peptide product has lower cost and no side effect, and the effect of relieving enteritis is remarkable. Therefore, the natural oyster zinc peptide product has a good prospect in development of medicines for preventing and treating enteritis.

The invention discloses a traditional Chinese medicine composition, a decoction, granules and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 5-15 parts of radix scutellariae, 3-7 parts of rhizoma coptidis, 5-15 parts of radix puerariae, 5-15 parts of radix paeoniae alba, 8-16 parts of radix angelicae sinensis, 5-15 parts of raw radix sanguisorbae, 10-20 parts of herba portulacae, 4-8 parts of radix aucklandiae and 3-7 parts of honey-fried licorice root. The traditional Chinese medicine composition not only can directly act on the cause of damp-heat, but also can comprehensively cover enteritis symptoms such as abdominal pain, diarrhea, tenesmus, bloody purulent stool and the like, can relieve the disadvantage that the stomach is injured by bitter and cold medicines, is strong in clinical pertinence, and is suitable for enteritis caused by ulcerative colitis, bacteria, viruses, radioactivity and the like; the traditional Chinese medicine composition can also be matched with probiotics to treat western medicine chronic diarrhea and traditional Chinese medicine diarrhea. Therefore, the traditional Chinese medicine composition or the decoction and the granules thereof have the prospect of being developed into the medicine for treating enteritis or the prospect of being developed into the medicine for treating western medicine chronic diarrhea and traditional Chinese medicine diarrhea in cooperation with the probiotics.

The application provides an EcNc engineering bacterium constitutively expressing MLH protein and application in treating intestinal inflammation, and belongs to the technical field of biological medicine. The application provides an EcNc engineering bacterium constitutively expressing MLH protein, taking Escherichia coli Nissle 1917 (EcN) as a chassis cell, and then introducing the reconstructed endogenous cryptic plasmid pMUT1 and / or pMUT2 after removing two hidden plasmids; the reconstruction is that a fusion protein MLH coding gene formed by using a flexible linker to connect SOD and CAT is inserted into pMUT1 and / or pMUT2. The application constructs an engineering bacterium constitutively expressing a fusion protein, and the engineering bacterium can express the fusion protein with double enzyme activities of SOD and CAT without antibiotic pressure and IPTG induction. The engineering bacterium constructed by the application can be used as an engineered microorganism for treating UC disease, for example, as a live bacterial drug.

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

The invention belongs to the technical field of microorganisms, and discloses a salmonella enteritidis bacteriophage PC571, a bacteriophage composition thereof and application of the bacteriophage PC571, the preservation number of the bacteriophage PC571 is CGMCC No.46168, and the bacteriophage PC571 is preserved in China General Microbiological Culture Collection Center on August 16, 2024. The salmonella enteritidis bacteriophage PC571 is wide in splitting spectrum, has good splitting capability on salmonella bacteriophage resistant bacteria, and can cooperate with other existing salmonella bacteriophages for bacteriostasis. The salmonella enteritidis bacteriophage PC571 or the bacteriophage composition thereof can be used as an active ingredient to prepare a pharmaceutical preparation, an environmental disinfectant, a bacteriostatic agent, a detection kit and the like for application. The salmonellosis in a livestock farm can be purified by mixing the phage with water and feed for a long time, and in addition, the phage is relatively high in safety, can effectively prevent and treat infection of salmonella with phage resistance, and has a market application prospect.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention belongs to the technical field of microbiological detection and molecular diagnosis, and discloses a primer group, a kit and a detection method for detecting salmonella enteritidis, the kit comprises an immunocapture component, an isothermal amplification component, a CRISPR / Cas12a detection component and auxiliary components; the isothermal amplification component is any one of an RPA (recombinase polymerase amplification) component or an LAMP (loop-mediated isothermal amplification) component, the RPA component comprises a specific primer group targeting 86th to 212th nucleotides in a salmonella enteritidis hilA gene coding region, and the LAMP component comprises a specific primer group targeting 58th to 250th nucleotides in the salmonella enteritidis hilA gene coding region. The primer group, the kit and the detection method for detecting the salmonella enteritidis successfully integrate three key technologies of RAP and LAMP rapid isothermal amplification, CRISPR / Cas12a high-specificity recognition and trans-cleavage and immunomagnetic bead targeted enrichment, and creatively provide the primer group, the kit and the detection method for detecting the salmonella enteritidis.

The invention relates to a big data screening method of a traditional Chinese medicine compound for treating enteritis and application thereof, and belongs to the field of traditional Chinese medicine screening based on a data mining technology, animal experiment efficacy investigation and network pharmacology prediction. Comprising the following steps: performing data arrangement specification on a traditional Chinese medicine compound for treating enteritis based on a data mining technology; analyzing and summarizing the standardized data to obtain a new traditional Chinese medicine compound (AEND); constructing an acute enteritis mouse model, and performing pharmacodynamic evaluation on the traditional Chinese medicine compound; predicting the action mechanism of the screened traditional Chinese medicine compound based on a network pharmacology method; a molecular docking technology is applied to virtually verify the action target of the traditional Chinese medicine compound on acute enteritis; the pathway protein of a mammalian cell receptor tyrosine kinase mediated phosphatidylinositol related (PI3K / AKT) signal pathway is detected. According to the invention, a new formula AEND is screened out based on data mining, and a pharmacological experiment verifies that the AEND has a protective effect on mice with acute enteritis. The developed traditional Chinese medicine compound has the effects of resisting inflammation and regulating the homeostasis of intestinal flora.

The invention discloses an application of an AC13 compound or a pharmaceutical salt thereof in preparation of a medicine for treating enteritis. The structure of the AC13 compound is shown in the specification. The AC13 compound disclosed by the invention has a remarkable treatment effect on enteritis as a small molecule compound, and has the characteristics of low toxicity and remarkable curative effect. Therefore, the AC13 compound can be used as a lead compound of the major disease enteritis, has important development prospects and clinical application values, and also provides a scientific basis for further exploring the enteritis pathogenesis mechanism.

The present invention provides a drug for treating and / or preventing enteritis and / or hepatitis, said drug containing D-amino acid as an active ingredient. In addition, the present invention provides a food composition for suppressing enteritis and / or hepatitis, said composition containing D-amino acid as an active ingredient. In addition, the present invention provides a method for assisting diagnosis of enteritis and / or hepatitis in a subject, said method using the amount of D-amino acid in the intestinal tract as an indicator.

The invention discloses a feed additive for replacing antibiotics to treat chicken necrotic enteritis and application of the feed additive, and belongs to the technical field of feed. The effective component of the feed additive is the tannin extract from chestnut trees, and animal experiments prove that the tannin extract from chestnut trees can improve the production performance of broiler chickens with necrotic enteritis to a certain extent, improve the intestinal morphology and immune function of the broiler chickens with necrotic enteritis and improve the immunity of the broiler chickens with necrotic enteritis. Therefore, the chestnut tree tannin extract can replace antibiotics and has a good treatment effect on broiler intestinal inflammation caused by clostridium perfringens and coccidiosis.

The invention discloses a construction method of a humanized enteritis mouse model, namely construction of an ulcerative colitis mouse model through DSS induction on an HSC-NCG-M / hIL15 immune reconstruction mouse, and belongs to the technical field of animal model construction. The method comprises the following steps: performing irradiation marrow removal on an NCG-M / hIL15 mouse, transplanting human hematopoietic stem cells and reconstructing, and then inducing ulcerative colitis by using DSS drinking water. The model constructed by the invention can better simulate the development process of IBD in a human immune system, solves the drug effect research defect caused by the difference between the existing mouse model and the human immune system, and provides a more accurate tool for IBD pathogenesis research and drug screening.

The invention belongs to the technical field of biological medicine, and discloses an enteritis targeted probiotic delivery system and a preparation method and application thereof, the system comprises: i) a recombinant plasmid for coding an anti-inflammatory functional protein, the plasmid comprising an anti-inflammatory peptide fragment, a surface protein modification and an antibiotic switch; ii) Escherichia coli chassis bacteria which are subjected to genetic engineering modification and have the capability of high yield of outer membrane vesicles; and iii) introducing the recombinant plasmid into the escherichia coli chassis bacterium to obtain a recombinant engineering bacterium. The delivery system disclosed by the invention can target intestinal inflammation parts, deliver anti-inflammatory proteins through the outer membrane vesicles, and specifically release anti-inflammatory factors in an inflammation microenvironment, so that intestinal inflammation response is relieved; according to the present invention, the method can achieve the precise targeting on the intestinal inflammation, can effectively control the remote delivery and the continuous secretion of the anti-inflammatory protein in space and time, has advantages of strong targeting property, lasting effect, small side effect and the like, and provides the new strategy for the safe and efficient treatment of the intestinal inflammation diseases.

The application discloses antagonistic Bacillus of Clostridium perfringens type G and application, the Bacillus is Bacillus sonorensis CB-6, and is classified and named as Bacillus sonorensis CB-6, the preservation number is CCTCC NO: M20251373, the preservation date is June 12, 2025, and the preservation unit is China Center for Type Culture Collection, which is located at Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province.The sterile fermentation supernatant of Bacillus sonorensis CB-6 provided by the application has neutral pH value, can inhibit Clostridium perfringens with high activity, the bacteriostatic effect is not dependent on organic acid such as lactic acid, the bacteriostatic effect is significant and stable, can significantly enhance the immunity of laying hens after Clostridium perfringens infection and improve the egg production rate, and solves the problem that laying hens are prone to necrotic enteritis during the egg production period and are not suitable for using antibiotics for prevention and control.

The application discloses a sophora japonica composition for refractory enteritis and a preparation method and application thereof. The sophora japonica composition for refractory enteritis comprises the following components: sophora japonica, dried orange peel, panax notoginseng, momordica grosvenori and lycoris radiata, and the sophora japonica composition for refractory enteritis is obtained by fermenting plant lactobacillus. The sophora japonica composition for refractory enteritis of the application can obviously increase the amount of duhrlactobacillus, lactobacillus and bifidobacterium and reduce the amount of clostridium in the process of treating inflammatory enteritis; can effectively inhibit the inflammation of colitis, and the mRNA level of inflammatory cytokines TNF-alpha, IL-22, IL-1beta and IL-6 is obviously reduced. The sophora japonica composition can obviously inhibit intestinal inflammation, promote the metabolism of intestinal short-chain fatty acids, increase the thickness of intestinal mucosa, and has obvious curative effects on intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa.